Preclinical data suggest synergy between these classes via PARP-induced DNA damage, cGAS-STING activation, and enhanced tumor immunogenicity, which may be amplified by PD-1/PD-L1 blockade. The gene discussed is PDCD1; the disease is neoplasm.